Skip to main content
Fig. 5 | Arthritis Research & Therapy

Fig. 5

From: DZ2002 ameliorates fibrosis, inflammation, and vasculopathy in experimental systemic sclerosis models

Fig. 5

DZ2002 reduced ICAM-1 and VCAM-1 in vivo and in vitro. a Western blot of ICAM-1 and VCAM-1 in BLM-induced SSc mice skin (DZ2002 = 50 mg/kg). b Survival rate of HMEC-1 at different concentrations of DZ2002 treatment. c Evaluation of mRNA levels of molecules associated with the upregulation of endothelial adhesion molecules in HMEC-1 by quantitative real-time reverse transcription-PCR, such as ICAM-1, VCAM-1, VEGF, bFGF, and ET-1. d Western blot of ICAM-1 and VCAM-1 in the HMEC-1 cells (TNF-α = 40 ng/ml, DZ2002 = 200 μM). e Representative photomicrographs showing the stained THP-1 cells on HMEC-1 cell layer (× 40, scale bar = 100 μm). The HMEC-1 cells were stimulated with TNF-a (40 ng/ml) with or without DZ2002 (200 μM). After 6 h incubation, those stained THP-1 cells adhered on HMEC-1 cell layer were counted. Mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001; ns no significance

Back to article page